Skip to content

Thermo Fisher Scientific TMO Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

GLW
CorningGLW
-$359M-19.3%
Illumina logo
IlluminaILMN
-$121M-147%
IQVIA logo
IQVIAIQV
-$381M-10.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$12.0B
Operating income$2.1B
Net income$1.7B+7.4%
EPS (diluted)$4.68+9.3%

Balance sheet

See full
Cash & equivalents$4.1B-11.7%
Total debt$39.2B+4.6%
Total equity$52.7B+4.3%
Total assets$113.17B+11.8%

Cash flow

See full
Operating cash flow$2.1B+51.9%
CapEx-$1.2B-509%
Free cash flow$923.0M-16.5%

Valuation

See full
Market cap$214.21B+17.7%
Enterprise value$249.32B+16.0%
P/E30.8×+3.1×
P/S4.8×-0.9×

Profitability

See full
Gross margin58.3%
Operating margin17.2%+0.8pp
Net margin15.2%+1.0pp
FCF margin15.7%-2.1pp

Returns & leverage

See full
Return on equity13.5%+0.1pp
Debt / equity0.7×0.0×
Current ratio1.6×-0.4×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Thermo Fisher Scientific’s 8-K, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation?
Thermo Fisher Scientific (TMO) reported cash provided by (used in) investing activity, including discontinued operation of $164M in Q2 2026.
How has Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation increased by 156.9% year-over-year, from -$288M to $164M.
What is the long-term trend for Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation?
Over 3 years (2021 to 2024), Thermo Fisher Scientific's cash provided by (used in) investing activity, including discontinued operation has grown at a -35.6% compound annual growth rate (CAGR), from -$21.93B to -$5.86B.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.